Mesothelioma Help - Mesothelioma is considered to be a relatively rare cancer form that is linked to chronic exposure to asbestos. There has been a pretty large decline in the number of exposures to asbestos ever since the 1970s, which is when asbestos stopped being used for most of its original intended building applications. Unfortunately, the incubation period associated with mesothelioma between when the initial exposure occurs and when the disease begins to show symptoms can take as long as between 20 years an 50 years. For this reason, the deaths associated with or related to this particular disease have risen significantly in recent years and are expected to continue following this path until the year 2020, fifty years following the last sanctioned use of asbestos. The anticipated increases in the incidence of this rare form of cancer has spurred a significant amount of interest in new cancer treatments and clinical cancer trials so that even newer and more powerful treatments can be developed for this deadly form of cancer.
Until recent years, the clinical trials that were being held for mesothelioma treatments were quite difficult to conduct. The mesothelioma cancer had a rapid onset, and its progression was rapid, and what this led to as a result was a relatively short period of survival that did not leave much time for the conducting of clinical trials. There was also a basic lack of understanding about the disease and its clinical biology, and nobody quite knew how the disease would change during its progression.
Specific clinical trials were put into place for the purpose of providing mesothelioma help, but none were quite doing their jobs at first. Specific clinical measures, for example, were near impossible to obtain in order to demonstrate how mesothelioma cancers were responding to the treatment. Recently, however, new metrics have been decided as a part of the Alimta clinical trial that have included factors beyond simple abnormal breathing capability or pleural thickening. Now there is additional mesothelioma help being provided by way of a number of new clinical trials, many of which are making use of these new measurement factors. It is hoped that these new measures will lead to greater mesothelioma help being provided so that the reverse of the mesothelioma cancer's progression can be achieved.
Clinical trials created for the purpose of evaluating treatments to provide mesothelioma help are broken into four different phases. The first phase involves evaluating a drug or a treatment in a small group of people, numbering between 20 and 80, to evaluate the drug's safety, identify any side effects and also determine the appropriate range of dosages. The second phase tests a larger group of patients to determine whether or not the treatment is effective at the dosage level recommended in the previous stage.
The third phase involves a larger group of patients and is designed to confirm the effectiveness of the treatment while evaluating its side effects. In this phase, the goal is to compare previous treatments with the currently tested treatment. Finally in the fourth phase, researchers follow up on third phase studies to obtain information usable for marketing the drug or treatment.